{
    "2021-07-12": [
        [
            {
                "time": "",
                "original_text": "CRO概念持续回暖，机构：新政释放资源，利好行业长期发展",
                "features": {
                    "keywords": [
                        "CRO概念",
                        "持续回暖",
                        "新政",
                        "释放资源",
                        "利好",
                        "长期发展"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "高瓴资本概念股恩捷股份再创新高，泰格医药、广联达、凯莱英、健帆生物跟涨",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "恩捷股份",
                        "新高",
                        "泰格医药",
                        "广联达",
                        "凯莱英",
                        "健帆生物",
                        "跟涨"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "科技",
                        "生物科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "公司研究：「凯莱英（002821）」高瓴豪掷10亿CDMO",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "高瓴资本",
                        "10亿",
                        "CDMO"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}